Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure

Table 3 Possible factors associated with survivors and non-survivors

Variables	Survivor (n = 4)	Non-survivor (n = 18)	P value
Age (yr)	40.00 ± 8.37	53.56 ± 14.58	0.0411
SIRS (yes), n (%)	0 (0)	4 (22.2)	-
Cirrhosis (yes), n (%)	2 (50)	11 (61)	0.6852
Acute/subacute/ACLF	0/2/2	1/6/11	-
TBil (mg/dL)	20.75 ± 6.67	22.94 ± 6.58	0.4961
ALT (IU/L)	195.75 ± 74.09	340.11 ± 205.69	0.2681
PTA (%)	30 .50 ± 5.26	28.17 ± 9.87	0.9961
MELD score	21.50 ± 2.08	30.61 ± 6.70	0.0151
Hepatic encephalopathy (yes), n (%)	1 (25)	8 (44)	0.4632
Ascites (yes), n (%)	2 (50)	14 (78)	0.2802
ANA (> 1:100)	4 (100)	18 (100)	-
IgG (mg/dL)	2483.50 ± 901.45	2344.88 ± 1119.46	0.5911
Corticosteroid treatment	4 (100)	3 (16.7)	0.0012
Plasma exchange, n (%)	1 (25)	3 (16.7)	1.0002

¹Mann-Whitney test;

²χ² test. ANA: Anti-nuclear antibody.